Quantinno Capital Management LP Sells 2,442 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Quantinno Capital Management LP decreased its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 32.7% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 5,031 shares of the biopharmaceutical company's stock after selling 2,442 shares during the period. Quantinno Capital Management LP's holdings in Regeneron Pharmaceuticals were worth $3,584,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Mufg Securities Americas Inc. bought a new position in Regeneron Pharmaceuticals during the 4th quarter valued at approximately $1,107,000. Nissay Asset Management Corp Japan ADV grew its position in Regeneron Pharmaceuticals by 3.6% during the 4th quarter. Nissay Asset Management Corp Japan ADV now owns 24,125 shares of the biopharmaceutical company's stock valued at $17,187,000 after purchasing an additional 847 shares during the last quarter. NorthRock Partners LLC raised its holdings in Regeneron Pharmaceuticals by 90.0% in the fourth quarter. NorthRock Partners LLC now owns 802 shares of the biopharmaceutical company's stock worth $571,000 after buying an additional 380 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Regeneron Pharmaceuticals by 2.1% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 82,519 shares of the biopharmaceutical company's stock worth $58,774,000 after buying an additional 1,712 shares in the last quarter. Finally, Mmbg Investment Advisors CO. purchased a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter valued at approximately $264,000. Institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ:REGN opened at $594.32 on Monday. The firm has a fifty day simple moving average of $599.96 and a two-hundred day simple moving average of $681.90. Regeneron Pharmaceuticals, Inc. has a 52 week low of $520.50 and a 52 week high of $1,211.20. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. The stock has a market capitalization of $64.17 billion, a P/E ratio of 15.53, a PEG ratio of 2.34 and a beta of 0.43.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing the consensus estimate of $8.83 by ($0.61). Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The company had revenue of $3.03 billion during the quarter, compared to analysts' expectations of $3.40 billion. During the same quarter in the prior year, the business posted $9.55 EPS. The company's revenue was down 3.7% on a year-over-year basis. On average, analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Tuesday, May 20th will be given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 0.59%. The ex-dividend date of this dividend is Tuesday, May 20th. Regeneron Pharmaceuticals's dividend payout ratio is currently 8.96%.

Analyst Ratings Changes

Several equities research analysts recently commented on REGN shares. Leerink Partners upgraded Regeneron Pharmaceuticals from a "market perform" rating to an "outperform" rating and lifted their price objective for the stock from $762.00 to $834.00 in a report on Wednesday, February 5th. UBS Group decreased their price objective on Regeneron Pharmaceuticals from $768.00 to $633.00 and set a "neutral" rating on the stock in a research note on Wednesday, April 30th. Royal Bank of Canada decreased their price objective on shares of Regeneron Pharmaceuticals from $1,051.00 to $943.00 and set an "outperform" rating on the stock in a research report on Wednesday, April 30th. Bernstein Bank cut their price target on Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research note on Tuesday, February 4th. Finally, Cantor Fitzgerald assumed coverage on Regeneron Pharmaceuticals in a research report on Tuesday, April 22nd. They issued an "overweight" rating and a $695.00 price objective on the stock. One analyst has rated the stock with a sell rating, four have given a hold rating, nineteen have assigned a buy rating and three have assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $890.60.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.